<DOC>
	<DOCNO>NCT00542724</DOCNO>
	<brief_summary>The purpose study demonstrate equivalent blood glucose control patient type 1 diabetes mellitus insulin VIAject™ regular human insulin prandial insulin demonstrate equivalent safety profile VIAject™ comparison regular human insulin .</brief_summary>
	<brief_title>An Open Label , Multi-Center , Randomized , Parallel Group Study Comparing Efficacy Safety Insulin VIAject™ Regular Human Insulin Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female patient type 1 diabetes must present following : Established diagnosis type 1 diabetes 1 year . HbA1c value 10.5 % . Three month stable insulin regimen meet current standard care include least two daily insulin injection . Age : 18 70 year . Body Mass Index : 18 38 Kg/m2 . Patients present follow include study : Type 2 diabetes mellitus determine investigator . History frequent severe hypoglycemia within prior six month . Cpeptide &gt; 1.0 ng/ml unless documented history ketoacidosis document history positive anti GAD test . History known hypersensitivity component study medication . History severe multiple allergy . Treatment investigational diabetes drug last 3 month treatment investigational drug last 30 day study entry . Current shortterm treatment systemic oral , injected , inhaled corticosteroid . ( inhaled corticosteroid may allow treatment longterm ) . Progressive disease likely prove fatal . History malignancy within past 5 year except basal cell epithelioma . Known significant hepatic disease serum AST ALT value ≥ 3 X upper limit normal bilirubin level ≥ 1.5 X upper limit normal . Severe complication diabetes mellitus include history finding Stage III IV diabetic retinopathy , proteinuria &gt; 2+ urine dipstick , serum creatinine &gt; 1.8 mg/dl male &gt; 1.5 mg/dl female , history renal transplant , severe peripheral vascular disease result amputation , chronic foot ulcer claudication absent pedal pulse . Known history autonomic neuropathy . History moderate severe ketoacidosis within 3 month precede screen study . Current drug alcohol abuse , history opinion Investigator impair patient safety protocol compliance . Current significant cardiovascular , respiratory , gastrointestinal , hepatic , renal , neurological , psychiatric and/or hematological disease evaluate Investigator . Blood donation within last 30 day . A woman breast feeding . Pregnant woman woman intend become pregnant study . A sexually active woman childbearing age actively consistently practice birth control use medically accept device therapy . Abnormal ECG , safety lab physical examination result , opinion investigator , render participation patient study inappropriate unsafe . A history lack compliance medical instruction , recent drug alcohol abuse , reason , opinion investigator , render participation patient study inappropriate unsafe . Current significant disease adrenal gland , pituitary gland thyroid discretion investigator . Glomerular Filtration Rate &lt; 40 ml/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Insulin</keyword>
	<keyword>Diabetes Mellitus type I</keyword>
	<keyword>Juvenile diabetes</keyword>
</DOC>